Sector News

J&J’s pharma unit ‘fastest-growing’ in the drug business, CEO Gorsky says

January 20, 2015
Life sciences
Johnson & Johnson’s new drugs came through again. Thanks to treatments from psoriasis-fighter Stelara to antipsychotic Invega Sustenna, the company’s pharma sales were up a whopping 25% in the U.S. for 2014, and 15% worldwide, to $32.4 billion.
 
CEO Alex Gorsky was quick to brag that J&J’s prescription drugs unit is the biggest in the U.S. and the fastest-growing pharma in the business. That’s a good thing for the company, particularly in the fourth quarter, because its pharma segment helped buoy less-than-fantastic results in consumer health, which only just brought some key brands back to full supply after 2010’s spate of recalls, and its medical devices unit. Fourth quarter sales were down slightly overall, thanks in part to currency effects.
 
But some tougher times are ahead. Fourth-quarter growth wasn’t as high as for the full year, partly because of a slowdown for one of the biggest performers in J&J’s pharma business last year, its hep C treatment Olysio. Approved late in 2013, Olysio topped $2.3 billion in global sales for 2014, a big chunk of overall drug revenue. The drug also won a new FDA indication in November, as a combo treatment with Gilead Sciences’ ($GILD) blockbuster Sovaldi. But even so, now that Gilead Sciences’ hep C combo pill Harvoni and AbbVie’s Viekira Pak are on the market, Olysio’s spot in hepatitis C cocktails is precarious.
 
So, those sales are now at risk. J&J felt the need to point out its pharma growth without hepatitis C–and its 2015 forecast includes the same qualifier. For the fourth quarter, pharma sales would have grown by 11.3% without its hep C franchise, compared with 13.9% including those meds.
 
Meanwhile, its anticoagulant Xarelto is facing some stepped up competition from Pfizer and Bristol-Myers Squibb’s big marketing push on Eliquis. Xarelto has staked out a big piece of the market for warfarin alternatives, but the Pfizer-BMS drug could endanger that. The prostate cancer drug Zytiga saw growth slide a bit during the fourth quarter, thanks to new competition from Medivation and Astellas’ treatment Xtandi. And Novartis’ new psoriasis fighter Cosentyx–approved in Japan and now Europe, with FDA’s decision coming soon–could prove to be strong competition for Stelara, thanks to some head-to-head trial data.
 
In fact, Goldman Sachs analyst Jami Rubin last week cut her recommendation on J&J stock to “sell” from “neutral,” because she’s looking for fewer new drugs this year from the company.
 
Ironically enough, any softness in the pharma business is expected to be offset in 2015 by the devices and consumer health segments, which are expected to do better this year than in previous years, CFO Dominic Caruso said during a call with analysts.
 
By Tracy Staton
 

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach